

**SCHEDULE OF INVESTMENTS**

March 31, 2019

**HEALTH CARE FUND**

|  | SHARES | VALUE             |  | SHARES | VALUE |
|--|--------|-------------------|--|--------|-------|
| <b>COMMON STOCKS† - 99.5%</b>                        |        |                   |  |        |       |
| <b>PHARMACEUTICALS - 33.7%</b>                       |        |                   |  |        |       |
| Johnson & Johnson                                    | 21,476 | \$ 3,002,130      |  |        |       |
| Pfizer, Inc.   | 56,211 | 2,387,281         |  |        |       |
| Merck & Company, Inc.                                | 27,273 | 2,268,295         |  |        |       |
| Eli Lilly & Co.                                      | 14,360 | 1,863,354         |  |        |       |
| AbbVie, Inc.   | 20,696 | 1,667,891         |  |        |       |
| Bristol-Myers Squibb Co.                             | 28,729 | 1,370,660         |  |        |       |
| CVS Health Corp.                                     | 22,713 | 1,224,912         |  |        |       |
| Cigna Corp.  | 7,173  | 1,153,562         |  |        |       |
| Zoetis, Inc.   | 10,667 | 1,073,847         |  |        |       |
| Allergan plc   | 7,158  | 1,048,003         |  |        |       |
| McKesson Corp.                                       | 6,075  | 711,139           |  |        |       |
| AmerisourceBergen Corp. — Class A                    | 7,781  | 618,745           |  |        |       |
| Teva Pharmaceutical Industries Ltd. ADR*             | 38,853 | 609,215           |  |        |       |
| Canopy Growth Corp.* <sup>1</sup>                    | 13,630 | 591,133           |  |        |       |
| Mylan N.V.*  | 20,299 | 575,274           |  |        |       |
| Jazz Pharmaceuticals plc*                            | 3,965  | 566,797           |  |        |       |
| Cardinal Health, Inc.                                | 11,489 | 553,195           |  |        |       |
| Novartis AG ADR                                      | 5,599  | 538,288           |  |        |       |
| Alkermes plc*  | 14,140 | 515,969           |  |        |       |
| Perrigo Company plc                                  | 10,587 | 509,870           |  |        |       |
| Tilray, Inc. — Class 2* <sup>1</sup>                 | 7,570  | 495,986           |  |        |       |
| AstraZeneca plc ADR                                  | 12,254 | 495,429           |  |        |       |
| Bausch Health Companies, Inc.*                       | 18,314 | 452,356           |  |        |       |
| DexCom, Inc.*  | 3,785  | 450,793           |  |        |       |
| Sarepta Therapeutics, Inc.*                          | 3,670  | 437,427           |  |        |       |
| Neurocrine Biosciences, Inc.*                        | 4,900  | 431,690           |  |        |       |
| PRA Health Sciences, Inc.*                           | 3,823  | 421,639           |  |        |       |
| Array BioPharma, Inc.*                               | 14,392 | 350,877           |  |        |       |
| Nektar Therapeutics*                                 | 10,327 | 346,987           |  |        |       |
| Global Blood Therapeutics, Inc.*                     | 4,920  | 260,416           |  |        |       |
| Heron Therapeutics, Inc.*                            | 8,940  | 218,494           |  |        |       |
| Mallinckrodt plc*                                    | 9,290  | 201,965           |  |        |       |
| <b>Total Pharmaceuticals</b>                         |        | <b>27,413,619</b> |  |        |       |
| <b>HEALTHCARE-PRODUCTS - 28.3%</b>                   |        |                   |  |        |       |
| Abbott Laboratories                                  | 22,758 | 1,819,274         |  |        |       |
| Thermo Fisher Scientific, Inc.                       | 5,923  | 1,621,244         |  |        |       |
| Danaher Corp.  | 11,438 | 1,510,045         |  |        |       |
| Stryker Corp.  | 6,703  | 1,323,977         |  |        |       |
| Becton Dickinson and Co.                             | 4,998  | 1,248,151         |  |        |       |
| Intuitive Surgical, Inc.*                            | 2,187  | 1,247,858         |  |        |       |
| Medtronic plc  | 13,128 | 1,195,698         |  |        |       |
| Boston Scientific Corp.*                             | 28,559 | 1,096,094         |  |        |       |
| Baxter International, Inc.                           | 12,484 | 1,015,074         |  |        |       |
| Edwards Lifesciences Corp.*                          | 5,186  | 992,237           |  |        |       |
| Zimmer Biomet Holdings, Inc.                         | 6,280  | 801,956           |  |        |       |
| Align Technology, Inc.*                              | 2,702  | 768,260           |  |        |       |
| IDEXX Laboratories, Inc.*                            | 3,081  | 688,912           |  |        |       |
| ResMed, Inc.   | 5,812  | 604,274           |  |        |       |
| Cooper Companies, Inc.                               | 1,987  | 588,490           |  |        |       |
| Hologic, Inc.*                                       | 12,036 | 582,542           |  |        |       |
| Teleflex, Inc.                                       | 1,890  | 571,082           |  |        |       |
| Varian Medical Systems, Inc.*                        | 3,946  | 559,227           |  |        |       |
| Dentsply Sirona, Inc.                                | 10,323 | 511,918           |  |        |       |
|  |        |                   |  |        |       |
| ABIOMED, Inc.*                                       | 1,788  | \$ 510,635        |  |        |       |
| LivaNova plc*  | 5,006  | 486,833           |  |        |       |
| Henry Schein, Inc.*                                  | 7,751  | 465,913           |  |        |       |
| Bio-Techne Corp.                                     | 2,118  | 420,529           |  |        |       |
| Masimo Corp.*  | 3,028  | 418,712           |  |        |       |
| Insulet Corp.* <sup>1</sup>                          | 3,750  | 356,587           |  |        |       |
| ICU Medical, Inc.*                                   | 1,440  | 344,635           |  |        |       |
| Integra LifeSciences Holdings Corp.*                 | 5,922  | 329,974           |  |        |       |
| NuVasive, Inc.*                                      | 4,792  | 272,138           |  |        |       |
| Tandem Diabetes Care, Inc.*                          | 4,110  | 260,985           |  |        |       |
| Inogen, Inc.*  | 2,290  | 218,397           |  |        |       |
| Patterson Companies, Inc.                            | 9,835  | 214,895           |  |        |       |
| <b>Total Healthcare-Products</b>                     |        | <b>23,046,546</b> |  |        |       |
| <b>BIOTECHNOLOGY - 19.1%</b>                         |        |                   |  |        |       |
| Amgen, Inc.  | 8,760  | 1,664,225         |  |        |       |
| Gilead Sciences, Inc.                                | 21,501 | 1,397,780         |  |        |       |
| Celgene Corp.*                                       | 13,430 | 1,266,986         |  |        |       |
| Regeneron Pharmaceuticals, Inc.*                     | 2,516  | 1,033,120         |  |        |       |
| Vertex Pharmaceuticals, Inc.*                        | 5,609  | 1,031,775         |  |        |       |
| illumina, Inc.*                                      | 3,306  | 1,027,141         |  |        |       |
| Biogen, Inc.*  | 3,757  | 888,080           |  |        |       |
| Alexion Pharmaceuticals, Inc.*                       | 6,172  | 834,331           |  |        |       |
| Incyte Corp.*  | 7,691  | 661,503           |  |        |       |
| BioMarin Pharmaceutical, Inc.*                       | 6,512  | 578,461           |  |        |       |
| Seattle Genetics, Inc.*                              | 7,017  | 513,925           |  |        |       |
| Ionis Pharmaceuticals, Inc.*                         | 6,250  | 507,312           |  |        |       |
| Alnylam Pharmaceuticals, Inc.*                       | 5,175  | 483,604           |  |        |       |
| Exact Sciences Corp.*                                | 5,307  | 459,692           |  |        |       |
| Bluebird Bio, Inc.*                                  | 2,820  | 443,671           |  |        |       |
| Sage Therapeutics, Inc.*                             | 2,750  | 437,387           |  |        |       |
| Exelixis, Inc.*                                      | 16,561 | 394,152           |  |        |       |
| United Therapeutics Corp.*                           | 2,926  | 343,425           |  |        |       |
| ACADIA Pharmaceuticals, Inc.*                        | 10,971 | 294,571           |  |        |       |
| Immunomedics, Inc.*                                  | 15,150 | 291,031           |  |        |       |
| Intercept Pharmaceuticals, Inc.*                     | 2,430  | 271,820           |  |        |       |
| Ligand Pharmaceuticals, Inc. — Class B* <sup>1</sup> | 1,920  | 241,363           |  |        |       |
| PTC Therapeutics, Inc.*                              | 6,090  | 229,228           |  |        |       |
| Myriad Genetics, Inc.*                               | 6,688  | 222,042           |  |        |       |
| <b>Total Biotechnology</b>                           |        | <b>15,516,625</b> |  |        |       |
| <b>HEALTHCARE-SERVICES - 13.4%</b>                   |        |                   |  |        |       |
| UnitedHealth Group, Inc.                             | 9,192  | 2,272,814         |  |        |       |
| Anthem, Inc.   | 4,414  | 1,266,730         |  |        |       |
| HCA Healthcare, Inc.                                 | 7,673  | 1,000,406         |  |        |       |
| Humana, Inc.   | 3,324  | 884,184           |  |        |       |
| IQVIA Holdings, Inc.*                                | 5,700  | 819,945           |  |        |       |
| Centene Corp.*                                       | 12,564 | 667,148           |  |        |       |
| WellCare Health Plans, Inc.*                         | 2,198  | 592,911           |  |        |       |
| Laboratory Corporation of America Holdings*          | 3,840  | 587,443           |  |        |       |
| Quest Diagnostics, Inc.                              | 5,919  | 532,236           |  |        |       |
| Universal Health Services, Inc. — Class B            | 3,943  | 527,455           |  |        |       |
| DaVita, Inc.*  | 8,344  | 452,996           |  |        |       |
| Molina Healthcare, Inc.*                             | 3,190  | 452,852           |  |        |       |
| Amedisys, Inc.*                                      | 2,430  | 299,522           |  |        |       |
| Teladoc Health, Inc.*                                | 5,180  | 288,008           |  |        |       |

**HEALTH CARE FUND**

|   | SHARES | VALUE             |   | FACE<br>AMOUNT | VALUE                |
|---|--------|-------------------|---|----------------|----------------------|
| Acadia Healthcare Company, Inc.* <sup>1</sup> | 8,095  | \$ 237,264        | <b>REPURCHASE AGREEMENTS</b> <sup>††2</sup> - 0.6%        |                |                      |
| <b>Total Healthcare-Services</b>              |        | <u>10,881,914</u> | JPMorgan Chase & Co.                                      |                |                      |
| <b>ELECTRONICS - 2.6%</b>                     |        |                   | issued 03/29/19 at 2.55%                                  |                |                      |
| Agilent Technologies, Inc.                    | 9,552  | 767,790           | due 04/01/19  | \$ 319,448     | \$ 319,448           |
| Waters Corp.*                                 | 2,647  | 666,276           | Bank of America Merrill Lynch                             |                |                      |
| Mettler-Toledo International, Inc.*           | 911    | <u>658,653</u>    | issued 03/29/19 at 2.55%                                  |                |                      |
| <b>Total Electronics</b>                      |        | <u>2,092,719</u>  | due 04/01/19  | 79,862         | 79,862               |
| <b>SOFTWARE - 2.0%</b>                        |        |                   | Barclays Capital  |                |                      |
| Veeva Systems, Inc. — Class A*                | 5,165  | 655,232           | issued 03/29/19 at 2.40%                                  |                |                      |
| Cerner Corp.*                                 | 11,433 | 654,082           | due 04/01/19  | 71,530         | <u>71,530</u>        |
| Medidata Solutions, Inc.*                     | 4,354  | <u>318,887</u>    | <b>Total Repurchase Agreements</b>                        |                |                      |
| <b>Total Software</b>                         |        | <u>1,628,201</u>  | (Cost \$470,840)  |                | <u>470,840</u>       |
| <b>COMMERCIAL SERVICES - 0.4%</b>             |        |                   |   | <b>SHARES</b>  |                      |
| HealthEquity, Inc.*                           | 4,070  | <u>301,099</u>    | <b>SECURITIES LENDING COLLATERAL</b> <sup>†3</sup> - 1.5% |                |                      |
| <b>Total Common Stocks</b>                    |        | <u>80,880,723</u> | <b>Money Market Fund</b>                                  |                |                      |
| (Cost \$63,318,761)                           |        |                   | First American Government                                 |                |                      |
|   |        |                   | Obligations Fund — Class Z, 2.32% <sup>4</sup>            | 1,213,236      | <u>1,213,236</u>     |
|   |        |                   | <b>Total Securities Lending Collateral</b>                |                |                      |
|   |        |                   | (Cost \$1,213,236)  |                | <u>1,213,236</u>     |
|   |        |                   | <b>Total Investments - 101.6%</b>                         |                |                      |
|   |        |                   | (Cost \$65,002,837)                                       |                | <u>\$ 82,564,799</u> |
|   |        |                   | <b>Other Assets &amp; Liabilities, net - (1.6)%</b>       |                | <u>(1,303,224)</u>   |
|   |        |                   | <b>Total Net Assets - 100.0%</b>                          |                | <u>\$ 81,261,575</u> |

\* Non-income producing security.

<sup>†</sup> Value determined based on Level 1 inputs.

<sup>††</sup> Value determined based on Level 2 inputs.

<sup>1</sup> All or a portion of this security is on loan at March 31, 2019.

<sup>2</sup> Repurchase Agreements.

<sup>3</sup> Securities lending collateral

<sup>4</sup> Rate indicated is the 7-day yield as of March 31, 2019.

ADR — American Depositary Receipt

plc — Public Limited Company